REGENXBIO to Pay $10M to GSK to Settle Sublicense Fee Dispute

summarizeSummary

REGENXBIO Inc. will make a $10.0 million payment to GlaxoSmithKline LLC to settle a dispute regarding sublicense fees, impacting the company's cash position amidst ongoing financial concerns.

check_boxKey Events

• Settlement Agreement Reached

  REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC (GSK) on March 18, 2026, to resolve a non-binding mediation related to a 2009 License Agreement.

• Mandatory $10 Million Payment

  The company will make a $10.0 million payment to GSK within three business days of the effective date for alleged underpayment of sublicense fees.

• Mutual Release of Claims

  The Settlement Agreement includes mutual releases of all past claims and certain specified types of future claims arising from the GSK-REGENXBIO Sublicense.

auto_awesomeAnalysis

REGENXBIO has agreed to pay GlaxoSmithKline LLC (GSK) $10.0 million to resolve a long-standing dispute over sublicense fees. This payment, representing a material cash outflow for the company, comes at a critical time given REGENXBIO's previously disclosed substantial doubt about its ability to continue as a going concern and recent FDA setbacks. While the settlement resolves past and certain future claims, the immediate financial impact is negative, reducing the company's cash runway.